Atopic dermatitis or atopic eczema is a chronic, relapsing, familial, symmetric and pruritic inflammatory skin disease that commonly presents during early infancy and childhood, but can persist or start in adulthood.
It is commonly associated with elevated serum immunoglobulin E levels and a personal or family history of allergies, allergic rhinitis and asthma.
It is one of the most common skin diseases afflicting both children and adults.
Although many patients with atopic dermatitis (AD) use antihistamines, no high-level evidence exists to prove that nonsedating antihistamines reduce itch in patients with AD or provide benefit in controlling AD symptoms, except perhaps sleep and AD comorbidities such as allergic rhinitis, according to a study.
Lebrikizumab, an interleukin (IL)-13 monoclonal antibody, taken every 4 weeks and in combination with topical corticosteroid (TCS) is safe and effective in patients with moderate-to-severe atopic dermatitis (AD), results from a phase II study have shown.
Atopic dermatitis (AD) in adults is associated with an increased risk of death, a recent study has found. Furthermore, AD patients have a slightly elevated risk of death from cardiovascular, urogenital and infectious diseases, but the absolute risk is very low.
Daily doses of the probiotic strains Bifidobacterium lactis CECT 8145, Bifidobacterium longum CECT 7347, and Lactobacillus casei CECT 9104 may reduce the SCORAD* index and need for topical steroids in children with moderate atopic dermatitis, according to a small study from Spain.
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that
can present in many different forms. However, it is principally
characterized by dry skin, intense itching, and the presence of
inflammatory skin lesions. [J Eur Acad Dermatol Venereol
2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet
Serum levels of squamous cell carcinoma antigen 2 (SCCA2) are indicative of disease severity and clinical type of atopic dermatitis (AD), according to a recent study, suggesting that SCCA2 may be a novel and useful marker for evaluating disease activity and treatment efficacy in AD.
There is a significant and disease severity‒dependent increased risk of developing conjunctivitis, keratitis and keratoconus in adults with atopic dermatitis (AD) compared with the general population, according to a recent study.
Repetitive, daily, high-frequency emollient therapy enhanced skin barrier integrity and function of premature and full-term neonates in communities with high relative humidity and temperature conditions, with sunflower seed oil (SSO) exhibiting a potential protective effect, according to a Nepalese study.
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.